SG10201913400QA - Methods for treating lung disorders - Google Patents

Methods for treating lung disorders

Info

Publication number
SG10201913400QA
SG10201913400QA SG10201913400QA SG10201913400QA SG10201913400QA SG 10201913400Q A SG10201913400Q A SG 10201913400QA SG 10201913400Q A SG10201913400Q A SG 10201913400QA SG 10201913400Q A SG10201913400Q A SG 10201913400QA SG 10201913400Q A SG10201913400Q A SG 10201913400QA
Authority
SG
Singapore
Prior art keywords
methods
treating lung
lung disorders
disorders
treating
Prior art date
Application number
SG10201913400QA
Inventor
Michael Baltezor
Matthew Mcclorey
William Johnston
Gere Dizerega
James Verco
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Publication of SG10201913400QA publication Critical patent/SG10201913400QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
SG10201913400QA 2017-06-14 2018-06-13 Methods for treating lung disorders SG10201913400QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762519257P 2017-06-14 2017-06-14
US201862628582P 2018-02-09 2018-02-09
US201862653942P 2018-04-06 2018-04-06
US201862678387P 2018-05-31 2018-05-31

Publications (1)

Publication Number Publication Date
SG10201913400QA true SG10201913400QA (en) 2020-03-30

Family

ID=62779154

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909837Y SG11201909837YA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders
SG10201913400QA SG10201913400QA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201909837Y SG11201909837YA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Country Status (10)

Country Link
US (3) US10398646B2 (en)
EP (1) EP3615004A1 (en)
JP (2) JP6840869B2 (en)
KR (2) KR20210118468A (en)
CN (2) CN110799176A (en)
AU (2) AU2018284247B2 (en)
BR (1) BR112019022720A2 (en)
CA (1) CA3063436A1 (en)
SG (2) SG11201909837YA (en)
WO (1) WO2018231908A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6921759B2 (en) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド Collection device and usage
KR102317108B1 (en) 2016-04-04 2021-10-25 크리티테크, 인크. Methods for treating solid tumors
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG11201909837YA (en) 2017-06-14 2019-11-28 Crititech Inc Methods for treating lung disorders
RU2020110399A (en) 2017-10-03 2021-11-09 Крититек, Инк. LOCAL DELIVERY OF ANTITUMOR PARTICLES IN COMBINATION WITH SYSTEM DELIVERY OF IMMUNOTHERAPY AGENTS FOR CANCER TREATMENT
BR112020021437A2 (en) * 2018-05-31 2021-01-19 Crititech, Inc. METHODS TO ISOLATE TUMOR-SPECIFIC IMMUNE CELLS FROM A SUBJECT TO ADOPTIVE CELL THERAPY AND CANCER VACCINES
WO2019231499A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for treatment of cancer
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
JP4865937B2 (en) 1997-06-27 2012-02-01 アブラクシス バイオサイエンス、エルエルシー Paclitaxel formulation
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP3418751B2 (en) 1998-01-22 2003-06-23 参天製薬株式会社 Fluorometholone suspension ophthalmic solution
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
US7179495B1 (en) 1998-11-25 2007-02-20 Universitaetsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
DE60024811T3 (en) 1999-05-27 2010-01-07 Acusphere, Inc., Watertown POROUS DRUG MATERIALS AND THEIR MANUFACTURING METHOD
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
JP2003513756A (en) 1999-11-12 2003-04-15 アンジオテック ファーマシューティカルズ,インコーポレイテッド Compositions of a combination of radiotherapy and a cell cycle inhibitor
KR100799089B1 (en) 1999-12-04 2008-01-29 리서치 디벨럽먼트 파운데이션 Composition for increasing the deposition of aerosolized drug
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
CA2445763A1 (en) 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
WO2003004142A1 (en) 2001-07-02 2003-01-16 Micro & Nano Materials Sagl Process for the production of micro and/or nano particles
WO2003015707A2 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
ES2625340T3 (en) 2001-10-15 2017-07-19 Crititech, Inc. Compositions and methods for the administration of poorly water soluble drugs and treatment methods
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
WO2003075977A2 (en) 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
AU2003230691A1 (en) 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1501483A2 (en) 2002-04-25 2005-02-02 Nektar Therapeutics UK Ltd Particulate materials
US20040092577A1 (en) 2002-04-26 2004-05-13 Lerner E. Itzhak Microparticle pharmaceutical compositions for intratumoral delivery
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (en) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 Process for the manufacture of pacilitaxel nano granule
KR100573289B1 (en) 2002-07-20 2006-04-24 대화제약 주식회사 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof
EP1569620A4 (en) * 2002-10-30 2006-03-22 Spherics Inc Nanoparticulate bioactive agents
KR100508518B1 (en) 2002-11-13 2005-08-17 한미약품 주식회사 Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby
LT1585548T (en) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
WO2004089291A2 (en) 2003-04-03 2004-10-21 Au Jessie L-S Tumor-targeting drug-loaded particles
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (en) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd Fine particle enclosing fat-soluble medicine, method for producing the same and preparation containing the same
AU2004283464B8 (en) 2003-10-15 2011-04-14 Syncore Biotechnology Co., Ltd Method of administering cationic liposomes comprising an active drug
WO2005042219A1 (en) 2003-10-24 2005-05-12 Ferro Corporation Method of forming particles
JP4787165B2 (en) * 2003-11-05 2011-10-05 エラン ファーマ インターナショナル,リミティド Nanoparticle compositions having peptides as surface stabilizers
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
EP1818093B1 (en) 2004-10-29 2014-03-12 Nara Machinery Co., Ltd. Method of granulating fine particles
WO2006068890A2 (en) 2004-12-14 2006-06-29 Transave, Inc. Lipid particles comprising bioactive agents, methods of preparing and uses thereof
ES2265262B1 (en) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) PROCEDURE FOR OBTAINING MICRO- AND NANODISPERSE SYSTEMS.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007010394A (en) * 2005-02-24 2008-02-19 Elan Pharma Int Ltd Nanoparticulate formulations of docetaxel and analogues thereof.
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
KR101380402B1 (en) 2005-03-31 2014-04-02 리드스 에이비 Kit for treating prostate related diseases
CN1923189A (en) 2005-08-30 2007-03-07 孔庆忠 Taxine kind anti-cancer slow release injection
WO2007027941A2 (en) 2005-08-31 2007-03-08 Abraxis Bioscience, Llc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009518167A (en) 2005-12-11 2009-05-07 エスセーエフ テクノロジーズ アクティーゼルスカブ Manufacture of nano-sized materials
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (en) 2006-01-20 2007-06-13 Eriochem Sa A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT
CN101336899A (en) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 Anticancer sustained-released injection containing taxane
DK1996160T3 (en) 2006-03-14 2010-07-05 Lidds Ab Controlled release bioresorbable composition
KR20080105174A (en) 2006-04-03 2008-12-03 테바 파마슈티컬 인더스트리즈 리미티드 Drug microparticles
CN101460147A (en) * 2006-04-03 2009-06-17 特瓦制药工业有限公司 Drug microparticles
EP2077823B1 (en) 2006-10-11 2012-06-27 Crititech, Inc. Method for precipitation of small medicament particles into use containers
WO2008118754A2 (en) 2007-03-23 2008-10-02 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
TWI405590B (en) 2007-04-06 2013-08-21 Activus Pharma Co Ltd Method of producing pulverized organic compound particle
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
KR20100020511A (en) * 2007-06-05 2010-02-22 파카 풀머네리 파마슈티칼즈, 인크. Compositions for delivering medicaments into the lungs, uses thereof
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
CN101129338A (en) 2007-08-27 2008-02-27 四川大学 Minuteness anti-cancer medicine paclitaxel of novel technique supercritical fluid
JP2011513412A (en) 2008-03-06 2011-04-28 日東電工株式会社 Pharmaceutical composition for treating cancer comprising a polymer paclitaxel conjugate
JP5536654B2 (en) 2008-09-19 2014-07-02 株式会社アクティバスファーマ Medical complex organic compound powder, method for producing the same, and suspension
CA2745238A1 (en) 2008-12-02 2010-06-10 Biocompatibles Uk Limited Pancreatic tumour treatment
PT104693B (en) 2009-07-27 2011-11-24 Univ Lisboa SEMI-SOLID LIPID NANOPARTICLES CONTAINING AN ANTINEOPLASTIC AGENT AND ITS PREPARATION PROCESS
JP2013502235A (en) 2009-08-24 2013-01-24 ベイラー カレッジ オブ メディスン Generation of specific CTL lines against multiple tumor antigens or viruses [cross-reference of related applications]
US8623329B1 (en) 2009-10-13 2014-01-07 Aerophase, Inc. Method for the treatment of lung tumors
CN102091062A (en) * 2009-12-11 2011-06-15 国家纳米技术与工程研究院 Method for treating lung cancer by sucking and administrating taxol
CN101829061A (en) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 Taxol nanoparticle composition and preparation method thereof
AU2011261684B2 (en) 2010-06-02 2016-09-15 Abraxis Bioscience, Llc Methods of treating bladder cancer
CA2811869A1 (en) 2010-09-21 2012-03-29 Cristal Delivery B.V. Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith
US20150093440A1 (en) 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
WO2012096995A2 (en) 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
DK2699233T3 (en) 2011-04-20 2017-07-10 Univ Sydney PARTICULAR MATERIAL AND CELLULAR TOXIN USED TO TREAT A SOLID TUMOR
US20140154269A1 (en) 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
CN107095863A (en) 2011-06-17 2017-08-29 博格有限责任公司 Inhalable drug composition
US10632131B2 (en) 2011-06-27 2020-04-28 Cristal Delivery B.V. Controlled release system
FR2980683B1 (en) * 2011-09-30 2014-11-21 Univ Paris Curie DEVICE FOR GUIDING A MEDICAL INSTRUMENT INSERTED IN A NATURAL PATH OR AN ARTIFICIAL PATH OF A PATIENT
CN102488682A (en) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 New application of chlorogenic acid in cancer resisting
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
TW201408304A (en) 2012-08-31 2014-03-01 Cathay General Hospital A combined drug with anti-cancer drug and hormone to treat renal cell carcinoma and its method of fabrication
AU2013318338B2 (en) 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
KR20160148723A (en) 2013-02-28 2016-12-26 화이자 인코포레이티드 Enhanced stability of novel liquid compositions
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
WO2014155146A1 (en) 2013-03-28 2014-10-02 Bbs Nanotechnology Llc Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
RU2719487C2 (en) 2013-12-17 2020-04-17 Дженентек, Инк. Methods of treating cancer using antagonists binding to components of the signal path pd-1, and taxanes
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
WO2015103005A1 (en) 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
TWI601542B (en) 2014-04-18 2017-10-11 林信湧 Inhalation-type pharmaceutical composition for lung cancer and preparation method thereof
US20150342872A1 (en) 2014-06-01 2015-12-03 Crititech, Inc. Use of Paclitaxel Particles
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
JP6921759B2 (en) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド Collection device and usage
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
JP6877049B2 (en) 2015-09-25 2021-05-26 ゼットワイ セラピューティクス インク.Zy Therapeutics Inc. Drug formulation based on granules containing polysaccharide-vitamin conjugate
DE202016006620U1 (en) 2015-10-28 2017-04-12 Qass Gmbh Devices for observing a magnetic field of a material volume
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
KR102317108B1 (en) 2016-04-04 2021-10-25 크리티테크, 인크. Methods for treating solid tumors
CN107281502B (en) 2016-04-05 2021-05-04 上海市肿瘤研究所 Composite developing temperature-sensitive gel suppository, preparation method and application thereof
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR20220151022A (en) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Carrier-pd-l1 binding agent compositions for treating cancers
ES2955884T3 (en) 2017-03-15 2023-12-07 Dfb Soria Llc Topical therapy for the treatment of skin malignancies with taxane nanoparticles
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG11201909837YA (en) 2017-06-14 2019-11-28 Crititech Inc Methods for treating lung disorders

Also Published As

Publication number Publication date
KR102303762B1 (en) 2021-09-23
US10398646B2 (en) 2019-09-03
US11160754B2 (en) 2021-11-02
CN110799176A (en) 2020-02-14
KR20200015479A (en) 2020-02-12
CA3063436A1 (en) 2018-12-20
AU2018284247B2 (en) 2020-04-30
JP2021075571A (en) 2021-05-20
AU2020204217B2 (en) 2021-11-18
AU2020204217A1 (en) 2020-07-16
KR20210118468A (en) 2021-09-30
JP6840869B2 (en) 2021-03-10
CN115919815A (en) 2023-04-07
RU2019134091A3 (en) 2021-11-08
JP2020523286A (en) 2020-08-06
US20180360748A1 (en) 2018-12-20
BR112019022720A2 (en) 2020-05-12
US10507181B2 (en) 2019-12-17
US20200060969A1 (en) 2020-02-27
AU2018284247A1 (en) 2019-11-07
US20190314277A1 (en) 2019-10-17
EP3615004A1 (en) 2020-03-04
RU2019134091A (en) 2021-07-14
WO2018231908A1 (en) 2018-12-20
SG11201909837YA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
HK1252741A1 (en) Compositions and methods for treating neurological disorders
HK1259336A1 (en) Methods for treating myeloproliferative disorders
IL285151A (en) Methods of treating fgf21-associated disorders
IL279308A (en) Methods for treating hepcidin-mediated disorders
IL269371A (en) Treatment methods
HK1256036A1 (en) Methods for treating myeloproliferative disorders
SG10201913400QA (en) Methods for treating lung disorders
HK1244217A1 (en) Methods for treating proteinopathies
EP3166610A4 (en) Methods for treating neurologic disorders
PT3119911T (en) Methods for treating neurological disorders
SG10202012106WA (en) Methods for treating inflammatory conditions of the lungs
IL255079A0 (en) Methods for treating lung cancer
IL281792A (en) Treatment methods
IL281839A (en) Treatment methods
HK1250624A1 (en) Methods for the treatment of cardiovascular disorders
GB201701933D0 (en) New methods for the treatment of hyperglycaemia
GB201701936D0 (en) New methods for the treatment of hyperglycaemia
GB201521542D0 (en) Methods for the treatment of cardiovascular disorders
GB201513991D0 (en) Methods for the treatment of cardiovascular disorders
GB201513344D0 (en) Methods for the treatment of Cardiovascular disorders
GB201413532D0 (en) Combination therapy for treating hearing disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201507109D0 (en) Methods for the treatment of cardiovascular disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201506228D0 (en) Methods For The Treatment Of Cardivascular Disorders